1. Início
  2. Publicações
  3. Health-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries

Health-Related Quality of Life and Mortality in Heart Failure The Global Congestive Heart Failure Study of 23000 Patients From 40 Countries

Data de publicação:

Autores da FMUP

  • José Carlos De Magalhães Silva Cardoso

    Autor

Participantes de fora da FMUP

  • Johansson, I
  • Joseph, P
  • Balasubramanian, K
  • McMurray, JJV
  • Lund, LH
  • Ezekowitz, JA
  • Kamath, D
  • Alhabib, K
  • Bayes-Genis, A
  • Budaj, A
  • Dans, ALL
  • Dzudie, A
  • Probstfield, JL
  • Fox, KAA
  • Karaye, KM
  • Makubi, A
  • Fukakusa, B
  • Teo, K
  • Temizhan, A
  • Wittlinger, T
  • Maggioni, AP
  • Lanas, F
  • Lopez-Jaramillo, P
  • Sliwa, K
  • Dokainish, H
  • Grinvalds, A
  • McCready, T
  • Yusuf, S
  • G-CHF Investigators

Unidades de investigação

Abstract

BACKGROUND: Poor health-related quality of life (HRQL) is common in heart failure (HF), but there are few data on HRQL in HF and the association between HRQL and mortality outside Western countries. METHODS: We used the Kansas City Cardiomyopathy Questionnaire-12 (KCCQ-12) to record HRQL in 23 291 patients with HF from 40 countries in 8 different world regions in the G-CHF study (Global Congestive Heart Failure). We compared standardized KCCQ-12 summary scores (adjusted for age, sex, and markers of HF severity) among regions (scores range from 0 to 100, with higher score indicating better HRQL). We used multivariable Cox regression with adjustment for 15 variables to assess the association between KCCQ-12 summary scores and the composite of all-cause death, HF hospitalization, and each component over a median follow-up of 1.6 years. RESULTS: The mean age of participants was 65 years; 61% were men; 40% had New York Heart Association class III or IV symptoms; and 46% had left ventricular ejection fraction >= 40%. Average HRQL differed between regions (lowest in Africa [mean +/- SE, 39.5 +/- 0.3], highest in Western Europe [62.5 +/- 0.4]). There were 4460 (19%) deaths, 3885 (17%) HF hospitalizations, and 6949 (30%) instances of either event. Lower KCCQ-12 summary score was associated with higher risk of all outcomes; the adjusted hazard ratio (HR) for each 10-unit KCCQ-12 summary score decrement was 1.18 (95% CI, 1.17-1.20) for death. Although this association was observed in all regions, it was less marked in South Asia, South America, and Africa (weakest association in South Asia: HR, 1.08 [95% CI, 1.03-1.14]; strongest association in Eastern Europe: HR, 1.31 [95% CI, 1.21-1.42]; interaction P<0.0001). Lower HRQL predicted death in patients with New York Heart Association class I or II and III or IV symptoms (HR, 1.17 [95% CI, 1.14-1.19] and HR, 1.14 [95% CI, 1.12-1.17]; interaction P=0.13) and was a stronger predictor for the composite outcome in New York Heart Association class I or II versus class III or IV (HR 1.15 [95% CI, 1.13-1.17] versus 1.09 [95% CI, [1.07-1.11]; interaction P<0.0001). HR for death was greater in ejection fraction >= 40 versus <40% (HR, 1.23 [95% CI, 1.20-1.26] and HR, 1.15 [95% CI, 1.13-1.17]; interaction P<0.0001). CONCLUSION: HRQL is a strong and independent predictor of all-cause death and HF hospitalization across all geographic regions, in mildly and severe symptomatic HF, and among patients with preserved and reduced ejection fraction.

Dados da publicação

ISSN/ISSNe:
0009-7322, 1524-4539

Circulation  Lippincott Williams and Wilkins Ltd.

Tipo:
Article
Páginas:
2129-2142
Link para outro recurso:
www.scopus.com

Citações Recebidas na Web of Science: 86

Citações Recebidas na Scopus: 140

Documentos

  • Não há documentos

Métricas

Filiações mostrar / ocultar

Keywords

  • health status; heart failure; prognosis; quality of life; ventricular function, left

Campos de estudo

Financiamento

Bayer AG

Proyectos asociados

Registo global de insuficiência cardíaca congestiva.

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Observacional Académico (IC_Congestiva) . 2019

This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms (EMPERIAL) - NCT03448406

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Ensaio Clínico Comercial (EMPERIAL) . Boehringer Ingelheim . 2020

Envolva-se com o seu coração: Promoção da adesão terapêutica com um sistema de telemonitorização para pessoas com insuficiência cardíaca crónica. (AdHeart)

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo de Intervenção Académico (AdHeart) . FCT . 2019

Sacubitril/Valsartan in everyday clinical practice: the experience of a heart failure clinic

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Clínico Académico (Sacubitril/Valsartan) . 2020

Avaliação da aorta ascendente em doentes operados a tetralogia de Fallot: implicações no follow-up clínico e imagiológico

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Clínico Académico . 2020

Hyperkalemia as a limiting factor of Neurohormonal Blockade/Modulation in everyday clinical practice

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Clínico Académico . 2020

Reversão da remodelagem ventricular na miocardiopatia dilatada idiopática

Investigador Principal: José Carlos de Magalhães Silva Cardoso

Estudo Clínico Académico . 2019

Citar a publicação

Partilhar a publicação